Rheumatoid arthritis and lung disease: From mechanisms to a practical approach

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 2, 2014, Pages 222-238

  Lake, Fiona ^a   Proudman, Susanna ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

anticitrullinated protein antibodies; biologic disease modifying antirheumatic drugs; drug induced; interstitial; lung; prognosis; rheumatoid arthritis

Indexed keywords

ACETYLCYSTEINE; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PEPTIDE ANTIBODY; PIRFENIDONE; PREDNISOLONE; RITUXIMAB;

ARTICLE; BRONCHIECTASIS; CORTICOSTEROID THERAPY; DISEASE COURSE; EXERCISE; HEALTH EDUCATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; ARTHRITIS, RHEUMATOID; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT CARE; PROCEDURES; PROGNOSIS;

ARTHRITIS, RHEUMATOID; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; PATIENT CARE TEAM; PROGNOSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897032659     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1371542     Document Type: Article

References (166)

1. van Nies J. A., Krabben A., Schoones J. W., Huizinga T. W., Kloppenburg M., van der Helm-van Mil A. H. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis: 2013; 0 1 10
2. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol: 2013; 25 3 360 366
3. Brown K. K. Rheumatoid lung disease. Proc Am Thorac Soc: 2007; 4 5 443 448 (Pubitemid 47435369)
4. O'Dwyer D. N., Armstrong M. E., Cooke G., Dodd J. D., Veale D. J., Donnelly S. C. Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med: 2013; 24 7 597 603
5. Kelly C., Hamilton J. What kills patients with rheumatoid arthritis? Rheumatology (Oxford): 2007; 46 2 183 184 (Pubitemid 46189772)
6. Young A., Koduri G., Batley M., et al. Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford): 2007; 46 2 350 357 (Pubitemid 46189799)
7. Bongartz T., Nannini C., Medina-Velasquez Y. F., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum: 2010; 62 6 1583 1591
8. Gizinski A. M., Mascolo M., Loucks J. L., et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol: 2009; 28 5 611 613
9. Chen J., Shi Y., Wang X., Huang H., Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol: 2013; 2013 406927
10. Deane K. D., Nicolls M. R. Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis. Arthritis Rheum: 2013; 65 4 864 868
11. Roubille C., Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum: 2013; pii: S0049-0172(13)00201-1
12. Doyle T. J., Hunninghake G. M., Rosas I. O. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med: 2012; 185 11 1147 1153
13. Picchianti Diamanti A., Germano V., Bizzi E., Laganà B., Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulm Med: 2011; 2011 931342
14. Ruderman E. M. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford): 2012; 51 06 vi37 vi43
15. Upchurch K. S., Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford): 2012; 51 06 vi28 vi36
16. Atzeni F., Boiardi L., Sallì S., Benucci M., Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol: 2013; 9 7 649 657
17. van Dartel S. AA, Fransen J., Kievit W., et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford): 2013; 52 6 1052 1057
18. Marigliano B., Soriano A., Margiotta D., Vadacca M., Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev: 2013; 12 11 1076 1084
19. Khurana R., Wolf R., Berney S., Caldito G., Hayat S., Berney S. M. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol: 2008; 35 9 1704 1708
20. Bruzzese V., Hassan C., Ridola L., Zullo A. Rheumatoid arthritis and cardiovascular risk: between lights and shadows. Curr Rheumatol Rev: 2013; 9 2 100 104
21. Corcoran J. P., Ahmad M., Mukherjee R., Redmond K. C. Pleuro-Pulmonary Complications of Rheumatoid Arthritis. Respir Care: 2013; (e-pub ahead of print). doi:10.4187/respcare.02597
22. Balbir-Gurman A., Yigla M., Nahir A. M., Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum: 2006; 35 6 368 378 (Pubitemid 43831160)
23. Perez T., Remy-Jardin M., Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med: 1998; 157 5 Pt 1 1658 1665
24. Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int: 2013; 33 7 1655 1667
25. Ramos-Casals M., Perez-Alvarez R., Perez-de-Lis M., Xaubet A., Bosch X.; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med: 2011; 124 5 386 394
26. Hadjinicolaou A. V., Nisar M. K., Bhagat S., Parfrey H., Chilvers E. R., Ostör A. J. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology (Oxford): 2011; 50 12 2297 2305
27. Holmqvist M. E., Neovius M., Eriksson J., et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA: 2012; 308 13 1350 1356
28. Kim S. C., Schneeweiss S., Liu J., Solomon D. H. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken): 2013; 65 10 1600 1607
29. Mercer L. K., Davies R., Galloway J. B., et al. British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford): 2013; 52 1 91 98
30. Rueth N., Andrade R., Groth S., D'Cunha J., Maddaus M. Pleuropulmonary complications of rheumatoid arthritis: a thoracic surgeon's challenge. Ann Thorac Surg: 2009; 88 3 e20 e21
31. Avnon L. S., Abu-Shakra M., Flusser D., Heimer D., Sion-Vardy N. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate? Rheumatol Int: 2007; 27 10 919 925 (Pubitemid 47084236)
32. Chapman P. T., O'Donnell J. L., Moller P. W. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol: 1992; 19 3 478 480
33. Nishida C., Yatera K., Kunimoto M., et al. [A case of rheumatoid arthritis with pneumothorax due to subpleural pulmonary rheumatoid nodules]. Nihon Kokyuki Gakkai Zasshi: 2008; 46 11 934 939
34. Ahmed R., Ahmed U., Syed I. Pneumothorax necessitans in a patient with trapped lung and rheumatoid arthritis. BMJ Case Rep: 2013; 2013;pii: bcr2013009263. doi: 10.1136/bcr-2013-009263
35. Nannini C., Medina-Velasquez Y. F., Achenbach S. J., et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken): 2013; 65 8 1243 1250
36. Greco A., Fusconi M., Macri G. F., et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. Am J Otolaryngol: 2012; 33 6 753 755
37. Mori S., Koga Y., Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol: 2011; 21 2 164 173
38. Fuld J. P., Johnson M. K., Cotton M. M., et al. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. Chest: 2003; 124 4 1224 1231 (Pubitemid 37290030)
39. Ayhan-Ardic F. F., Oken O., Yorgancioglu Z. R., Ustun N., Gokharman F. D. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol: 2006; 25 2 213 218 (Pubitemid 43372320)
40. Hayakawa H., Sato A., Imokawa S., Toyoshima M., Chida K., Iwata M. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med: 1996; 154 5 1531 1536 (Pubitemid 26391209)
41. Devouassoux G., Cottin V., Lioté H., et al. Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERMOP). Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J: 2009; 33 5 1053 1061
42. Schwarz M. I., Lynch D. A., Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis? Eur Respir J: 1994; 7 4 817 820 (Pubitemid 24122981)
43. Wilczynska M. M., Condliffe A. M., McKeon D. J. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care: 2013; 58 4 694 701
44. Gabbay E., Tarala R., Will R., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med: 1997; 156 2 Pt 1 528 535 (Pubitemid 27351990)
45. Dawson J. K., Fewins H. E., Desmond J., Lynch M. P., Graham D. R. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax: 2001; 56 8 622 627 (Pubitemid 32706144)
46. Youssef A. A., Machaly S. A., El-Dosoky M. E., El-Maghraby N. M. Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing. Rheumatol Int: 2012; 32 7 1985 1995
47. Wilsher M., Voight L., Milne D., et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med: 2012; 106 10 1441 1446
48. Schreiber J., Koschel D., Kekow J., Waldburg N., Goette A., Merget R. Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med: 2010; 21 3 168 172
49. Sharma S., Vaccharajani A., Mandke J. Severe pulmonary hypertension in rheumatoid arthritis. Int J Cardiol: 1990; 26 2 220 222 (Pubitemid 20035672)
50. Castro G. W., Appenzeller S., Bertolo M. B., Costallat L. T. Isolated pulmonary hypertension secondary to rheumatoid arthritis. Clin Rheumatol: 2006; 25 6 901 903 (Pubitemid 44473165)
51. Udayakumar N., Venkatesan S., Rajendiran C. Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease. Int J Cardiol: 2008; 127 3 410 412 (Pubitemid 351885079)
52. Blumentals W. A., Arreglado A., Napalkov P., Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord: 2012; 13 158 168
53. Listing J., Gerhold K., Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford): 2013; 52 1 53 61
54. Coyne P., Hamilton J., Heycock C., Saravanan V., Coulson E., Kelly C. A. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol: 2007; 34 9 1832 1836 (Pubitemid 350067642)
55. Wells A. U., Ward S. Pulmonary function tests in idiopathic pulmonary fibrosis. In: Meyer K. C., Nathan S. D., eds. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide, Respiratory Medicine. Vol. 9. Springer Science + Business Media New York: 2014
56. Koduri G., Norton S., Young A., et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford): 2010; 49 8 1483 1489
57. Weyand C. M., Schmidt D., Wagner U., Goronzy J. J. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum: 1998; 41 5 817 822 (Pubitemid 28225781)
58. Saag K. G., Kolluri S., Koehnke R. K., et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum: 1996; 39 10 1711 1719 (Pubitemid 26331025)
59. Gochuico B. R., Avila N. A., Chow C. K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med: 2008; 168 2 159 166 (Pubitemid 351185882)
60. Biederer J., Schnabel A., Muhle C., Gross W. L., Heller M., Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol: 2004; 14 2 272 280 (Pubitemid 38181084)
61. Mori S., Koga Y., Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med: 2012; 106 11 1591 1599
62. Klareskog L., Stolt P., Lundberg K., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum: 2006; 54 1 38 46 (Pubitemid 43122184)
63. Bongartz T., Cantaert T., Atkins S. R., et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford): 2007; 46 1 70 75 (Pubitemid 44932787)
64. Harlow L., Rosas I. O., Gochuico B. R., et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum: 2013; 65 4 869 879
65. Nishimura K., Sugiyama D., Kogata Y., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med: 2007; 146 11 797 808 (Pubitemid 351650500)
66. Fischer A., Solomon J. J., du Bois R. M., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med: 2012; 106 7 1040 1047
67. Giles J. T., Danoff S. K., Sokolove J., et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis: 2013; (e-pub ahead of print). doi:10.1136/annrheumdis-2012-203160
68. Willis V. C., Demoruelle M. K., Derber L. A., et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum: 2013; 65 10 2545 2554
69. Turesson C., Jacobsson L. T., Sturfelt G., Matteson E. L., Mathsson L., Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis: 2007; 66 1 59 64 (Pubitemid 46044861)
70. Suzuki A., Ohosone Y., Obana M., et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol: 1994; 21 1 33 36 (Pubitemid 24044913)
71. Sihvonen S., Korpela M., Laippala P., Mustonen J., Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol: 2004; 33 4 221 227 (Pubitemid 39180164)
72. Travis W. D., Costabel U., Hansell D. M., et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med: 2013; 188 6 733 748
73. Flaherty K. R., Colby T. V., Travis W. D., et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med: 2003; 167 10 1410 1415 (Pubitemid 36609727)
74. Vij R., Noth I., Strek M. E. Autoimmune-featured interstitial lung disease: a distinct entity. Chest: 2011; 140 5 1292 1299
75. Larsen B. T., Colby T. V. Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med: 2012; 136 10 1234 1241
76. Wells A. U. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)-practical implications. Respir Res: 2013; 14 01 S2
77. Castelino F. V., Goldberg H., Dellaripa P. F. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford): 2011; 50 3 489 493
78. Vij R., Strek M. E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest: 2013; 143 3 814 824
79. Cottin V., Cordier J. F. Subclinical interstitial lung disease: no place for crackles? Am J Respir Crit Care Med: 2012; 186 3 289, author reply 289-290
80. Lee H. K., Kim D. S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest: 2005; 127 6 2019 2027
81. Yoshinouchi T., Ohtsuki Y., Fujita J., et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int: 2005; 26 2 121 125 (Pubitemid 41779820)
82. Rees J. H., Woodhead M. A., Sheppard M. N., du Bois R. M. Rheumatoid arthritis and cryptogenic organising pneumonitis. Respir Med: 1991; 85 3 243 246
83. Cohen A. J., King T. E. Jr, Downey G. P. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med: 1994; 149 6 1670 1675 (Pubitemid 24175993)
84. Ippolito J. A., Palmer L., Spector S., Kane P. B., Gorevic P. D. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum: 1993; 23 1 70 78 (Pubitemid 23270894)
85. Rajasekaran A., Shovlin D., Saravanan V., Lord P., Kelly C. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol: 2006; 33 7 1250 1253 (Pubitemid 44025136)
86. Tansey D., Wells A. U., Colby T. V., et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology: 2004; 44 6 585 596 (Pubitemid 38845105)
87. Hamblin M. J., Horton M. R. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med: 2011; 2011 872120
88. de Lauretis A., Veeraraghavan S., Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis: 2011; 8 1 53 82
89. Mori S., Cho I., Koga Y., Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol: 2008; 35 8 1513 1521
90. Kim E. J., Collard H. R., King T. E. Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest: 2009; 136 5 1397 1405
91. Wells A. U. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev: 2013; 22 128 158 162
92. Schmidt S. L., Sundaram B., Flaherty K. R. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology: 2009; 14 7 934 939
93. Tanaka N., Kim J. S., Newell J. D., et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology: 2004; 232 1 81 91 (Pubitemid 38796446)
94. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet: 2012; 380 9842 689 698
95. Goh N. S., Desai S. R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med: 2008; 177 11 1248 1254 (Pubitemid 351860934)
96. Walsh S. LF, Sverzellati N., Devaraj A., Keir G. J., Wells A. U., Hansell D. M. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax: 2013
97. Song J-W, Lee H-K, Lee Et Al C. K. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis: 2013; 30 2 103 112
98. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest: 1988; 93 1 114 118 (Pubitemid 18037267)
99. Solomon J. J., Ryu J. H., Tazelaar H. D., et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med: 2013; 107 8 1247 1252
100. Tsuchiya Y., Takayanagi N., Sugiura H., et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J: 2011; 37 6 1411 1417
101. Hubbard R., Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford): 2002; 41 6 676 679 (Pubitemid 34618887)
102. Park J. H., Kim D. S., Park I. N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med: 2007; 175 7 705 711
103. Ryerson C. J., Urbania T. H., Richeldi L., et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J: 2013; 42 3 750 757
104. Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J: 2010; 35 6 1206 1208
105. Vassallo R., Matteson E., Thomas C. F. Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest: 2002; 122 3 1093 1096
106. Chang H. K., Park W., Ryu D. S. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci: 2002; 17 2 270 273
107. Kobayashi A., Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol: 2012; 5 2 219 227
108. Puttick M. P., Klinkhoff A. V., Chalmers A., Ostrow D. N. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol: 1995; 22 11 2163 2165
109. Danoff S. K., Schonhoft E. H. Role of support measures and palliative care. Curr Opin Pulm Med: 2013; 19 5 480 484
110. Gilbert C. R., Smith C. M. Advanced lung disease: quality of life and role of palliative care. Mt Sinai J Med: 2009; 76 1 63 70
111. Meyer K. C. Management of interstitial lung disease in elderly patients. Curr Opin Pulm Med: 2012; 18 5 483 492
112. Kim S. H., Yoo W. H. Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature. Rheumatol Int: 2011; 31 7 919 922
113. Camus P. The Drug-Induced Respiratory Disease Web site. Available at: www.pneumotox.com. Accessed October 21, 2013
114. Goodwin S. D., Glenny R. W. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med: 1992; 152 7 1521 1524
115. Vogts N., Young S. Pulmonary infiltrates with eosinophilia syndrome in ibuprofen overdose. N Z Med J: 2012; 125 1360 74 75
116. Ethgen O., de Lemos Esteves F., Bruyere O., Reginster J. Y. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin: 2013; 29 9 1147 1160
117. Dixon W. G., Suissa S., Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther: 2011; 13 4 R139
118. Dixon W. G., Abrahamowicz M., Beauchamp M. E., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis: 2012; 71 7 1128 1133
119. Chikura B., Sathi N., Lane S., Dawson J. K. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford): 2008; 47 11 1647 1650
120. Collins K., Aspey H., Todd A., Saravanan V., Rynne M., Kelly C. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatology (Oxford): 2008; 47 1 109 110 (Pubitemid 350286278)
121. Kremer J. M., Alarcón G. S., Weinblatt M. E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate- associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum: 1997; 40 10 1829 1837 (Pubitemid 27452534)
122. Alarcón G. S., Kremer J. M., Macaluso M., et al. Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann Intern Med: 1997; 127 5 356 364 (Pubitemid 27362743)
123. Kramer N., Chuzhin Y., Kaufman L. D., Ritter J. M., Rosenstein E. D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum: 2002; 47 6 670 671 (Pubitemid 35461322)
124. Dayton C. S., Schwartz D. A., Sprince N. L., et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med: 1995; 151 4 1189 1193
125. Dawson J. K., Graham D. R., Desmond J., Fewins H. E., Lynch M. P. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford): 2002; 41 3 262 267 (Pubitemid 34537861)
126. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum: 2006; 54 5 1435 1439
127. Chikura B., Lane S., Dawson J. K. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford): 2009; 48 9 1065 1068
128. Sawada T., Inokuma S., Sato T., et al. Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford): 2009; 48 9 1069 1072
129. Tomioka R., King T. E. Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med: 1997; 155 3 1011 1020
130. van de Laar M. A., Westermann C. J., Wagenaar S. S., Dinant H. J. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum: 1985; 28 1 93 97 (Pubitemid 15193027)
131. Furst D. E., Keystone E. C., So A. K., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis: 2013; 72 02 ii2 ii34
132. Mariette X., Gottenberg J. E., Ravaud P., Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford): 2011; 50 1 222 229
133. Koike T., Harigai M., Inokuma S., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol: 2009; 36 5 898 906
134. Peno-Green L., Lluberas G., Kingsley T., Brantley S. Lung injury linked to etanercept therapy. Chest: 2002; 122 5 1858 1860 (Pubitemid 35366106)
135. Ognenovski V. M., Ojo T. C., Fox D. A. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol: 2008; 35 11 2279 2282
136. Toussirot E., Berthelot J. M., Pertuiset E., et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol: 2009; 36 11 2421 2427
137. Ostör A. J., Chilvers E. R., Somerville M. F., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol: 2006; 33 3 622 628 (Pubitemid 43334590)
138. Tai T. L., O'Rourke K. P., McWeeney M., Burke C. M., Sheehan K., Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford): 2002; 41 8 951 952
139. Huggett M. T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford): 2006; 45 10 1312 1313
140. Dixon W. G., Hyrich K. L., Watson K. D., et al. B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis: 2010; 69 3 522 528
141. Fleischmann R. M., Tesser J., Schiff M. H., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis: 2006; 65 8 1006 1012 (Pubitemid 44133261)
142. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis: 2009; 68 1 25 32
143. Soubrier M., Jeannin G., Kemeny J. L., et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine: 2008; 75 3 362 365
144. Matteson E. L., Bongartz T., Ryu J. H., et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmun Dis: 2012; 2 3 53 58
145. Teichmann L. L., Woenckhaus M., Vogel C., Salzberger B., Schölmerich J., Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford): 2008; 47 8 1256 1257 (Pubitemid 352038242)
146. Lee Y. H., Bae S. C., Song G. G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int: 2011; 31 11 1493 1499
147. Strangfeld A., Eveslage M., Schneider M., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis: 2011; 70 11 1914 1920
148. Gottenberg J. E., Ravaud P., Bardin T., et al. AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum: 2010; 62 9 2625 2632
149. Franklin J., Lunt M., Bunn D., Symmons D., Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis: 2007; 66 3 308 312 (Pubitemid 46579629)
150. McLean-Tooke A., Aldridge C., Waugh S., Spickett G. P., Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford): 2009; 48 8 867 871
151. Housden M. M., Bell G., Heycock C. R., Hamilton J., Saravanan V., Kelly C. A. How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. Clin Med: 2010; 10 4 326 329
152. Kameda H., Tokuda H., Sakai F., et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med: 2011; 50 4 305 313
153. Singh J. A., Furst D. E., Bharat A., et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care res: 2012; 64 625 639
154. Mori S., Tokuda H., Sakai F., et al. NTM-BIORA (NTM infection in Biologic-treated RA patients) Study Investigators. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Mod Rheumatol: 2012; 22 5 727 737
155. Mori S., Sugimoto M. Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection?: Case presentation and literature review. Clin Rheumatol: 2012; 31 2 203 210
156. Yamakawa H., Takayanagi N., Miyahara Y., et al. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J Rheumatol: 2013; 40 8 1307 1315
157. Lacaille D., Guh D. P., Abrahamowicz M., Anis A. H., Esdaile J. M. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum: 2008; 59 8 1074 1081
158. Puéchal X., Fajac I., Bienvenu T., et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J: 1999; 13 6 1281 1287 (Pubitemid 29357143)
159. Puéchal X., Bienvenu T., Génin E., et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis: 2011; 70 4 653 659
160. Mikuls T. R. Rheumatoid arthritis incidence: what goes down must go up? Arthritis Rheum: 2010; 62 6 1565 1567
161. Gabriel S. E., Crowson C. S., Kremers H. M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum: 2003; 48 1 54 58 (Pubitemid 36091647)
162. Glace B., Gottenberg J. E., Mariette X., et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis: 2012; 71 8 1429 1431
163. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum: 2011; 41 2 256 264
164. Scherak O., Popp W., Kolarz G., Wottawa A., Ritschka L., Braun O. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol: 1993; 20 6 944 949 (Pubitemid 23203231)
165. Dixon W. G., Hyrich K. L., Watson K. D., Lunt M., Symmons D. P.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis: 2010; 69 6 1086 1091
166. Baughman R. P., Meyer K. C., Nathanson I., et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2012; 142 5 e1S e111S